Abstract

The hydrolysis of bradykinin (Bk) by different classes of proteases in plasma and tissues leads to a decrease in its half-life. Here, Bk actions on smooth muscle and in vivo cardiovascular assays in association with a protease inhibitor, Black eyed-pea trypsin and chymotrypsin inhibitor (BTCI) and also under the effect of trypsin and chymotrypsin were evaluated. Two synthetic Bk-related peptides, Bk1 and Bk2, were used to investigate the importance of additional C-terminal amino acid residues on serine protease activity. BTCI forms complexes with Bk and analogues at pH 5.0, 7.4 and 9.0, presenting binding constants ranging from 103 to 104 M−1. Formation of BTCI-Bk complexes is probably driven by hydrophobic forces, coupled with slight conformational changes in BTCI. In vitro assays using guinea pig (Cavia porcellus) ileum showed that Bk retains the ability to induce smooth muscle contraction in the presence of BTCI. Moreover, no alteration in the inhibitory activity of BTCI in complex with Bk and analogous was observed. When the BTCI and BTCI-Bk complexes were tested in vivo, a decrease of vascular resistance and consequent hypotension and potentiating renal and aortic vasodilatation induced by Bk and Bk2 infusions was observed. These results indicate that BTCI-Bk complexes may be a reliable strategy to act as a carrier and protective approach for Bk-related peptides against plasma serine proteases cleavage, leading to an increase in their half-life. These findings also indicate that BTCI could remain stable in some tissues to inhibit chymotrypsin or trypsin-like enzymes that cleave and inactivate bradykinin in situ.

Highlights

  • Bradykinin (Bk) is an endogenous biologically active peptide with nine amino acid residues (Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9), which is physiologically cleaved from kininogen by serine proteases, such as kallikreins

  • Our findings indicate that Black eyed-pea trypsin and chymotrypsin inhibitor (BTCI) could remain stable in some tissues to inhibit chymotrypsin or trypsin-like enzymes that cleave and inactivate bradykinin in situ

  • We showed the actions of Bk and Bk-related peptides on smooth muscle in the presence of BTCI and under the effect of the serine proteases trypsin and chymotrypsin, as well as in vivo effects of the peptides, isolated and associated with BTCI, in renal and aortic vascular reactivity

Read more

Summary

Introduction

Bradykinin (Bk) is an endogenous biologically active peptide with nine amino acid residues (Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9), which is physiologically cleaved from kininogen by serine proteases, such as kallikreins. Non-mammalian bradykinin-related peptides, including those from amphibian, show primary structure differences, which are consistent with functional specificities. Bradykinin and related kinins act in the constriction and vasodilatation of smooth muscle, as well as promoting arterial hypotension acting on two types of receptors, B1 and B2. Whereas B1 receptors are barely expressed in normal tissues, being up-regulated after lesion and inflammation [3], B2 receptors are responsible for most of the physiological effects of the kinins, including arterial vasodilatation, and peripheral smooth muscle contraction (stomach, colon, urinary bladder, uterus, and the ileum) [4,5]

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call